AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Besse, Benjamin
Felip, Enriqueta
Clifford, Corinne
Louie-Gao, Melinda
Green, Jennifer
Turner, Christopher D.
Popat, Sanjay
机构：
[1] Gustave Roussy Univ Paris Sud, Villejuif, France
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Blueprint Med Inc, Cambridge, MA USA
[4] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9633
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
    Thomas, M.
    Griesinger, F.
    Schuler, M.
    Gainor, J. F.
    Curigliano, G.
    Kim, D. -W.
    Lee, D. H.
    Besse, B.
    Baik, C. S.
    Doebele, R. C.
    Cassier, P.
    Lopes, G.
    Tan, D. S. -W.
    Garralda, E.
    Paz-Ares, L.
    Cho, Chul B.
    Gadgeel, S. M.
    Liu, S. V.
    Turner, C. D.
    Subbiah, V.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 141 - 142
  • [22] Durability of Efficacy with Selpercatinib in Patients (pts) with RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)
    Drillon, Alexander E.
    Subbiah, Vivek
    Gautschi, Oliver
    Tomasini, Pascale
    De Braud, Filippo G.
    Solomon, Benjamin
    Tan, Daniel Shao-Weng
    Alonso, Guzman
    Wolf, Juergen
    Park, Keunchil
    Goto, Koichi
    Soldatenkova, Victoria
    Szymczak, Sylwia
    Barker, Scott S.
    Puri, Tarun
    Lin, Aimee K.
    Loong, Herbert
    Besse, Benjamin
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 150 - 150
  • [23] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. ONKOLOGIE, 2003, 26 : 26 - 32
  • [24] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Hidehito Horinouchi
    Noboru Yamamoto
    Hiroshi Nokihara
    Takeshi Horai
    Makoto Nishio
    Fumiyoshi Ohyanagi
    Atsushi Horiike
    Kazuhiko Nakagawa
    Masaaki Terashima
    Takafumi Okabe
    Hiroyasu Kaneda
    Mark D. McKee
    Dawn M. Carlson
    Hao Xiong
    Tomohide Tamura
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 37 - 43
  • [25] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC).: Across
    Domènech, M
    Losa, F
    Blanco, R
    Nogué, M
    Montesinos, J
    Mesía, C
    Gallardo, E
    de Olaguer, JP
    [J]. LUNG CANCER, 2005, 49 : S242 - S242
  • [26] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Horai, Takeshi
    Nishio, Makoto
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Nakagawa, Kazuhiko
    Terashima, Masaaki
    Okabe, Takafumi
    Kaneda, Hiroyasu
    McKee, Mark D.
    Carlson, Dawn M.
    Xiong, Hao
    Tamura, Tomohide
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 37 - 43
  • [27] Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer:: a lung cancer Galician group phase II study
    Casal, Joaquin
    Amenedo, Margarita
    Mel, Jose Ramon
    Anton, Luis Miguel
    Rodriguez-Lopez, Ruben
    Lopez-Lopez, Rafael
    Gonzalez-Ageitos, Ana
    Castellanos, Javier
    Constenla, Manuel
    Tisaire, Jose L.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 725 - 732
  • [28] Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study
    Joaquín Casal
    Margarita Amenedo
    José Ramón Mel
    Luis Miguel Antón
    Rubén Rodríguez-López
    Rafael López-López
    Ana González-Ageitos
    Javier Castellanos
    Manuel Constenla
    José L. Tisaire
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 60 : 725 - 732
  • [29] Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer
    Ban, Heejung
    Kim, Kyu-Sik
    Oh, In-Jae
    Yoon, Seong-Hoon
    Lee, Boram
    Yu, Jinyeong
    Kim, Sunmin
    Lee, Ho-Sung
    Shin, Hong-Joon
    Park, Cheol-Kyu
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    [J]. THORACIC CANCER, 2014, 5 (06) : 525 - 529
  • [30] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC). The ACROSS Study
    Domenech, Montse
    Losa, Ferran
    Blanco, Remei
    Nogue, Miquel
    Montesinos, Jesus
    Mesia, Carles
    Gallardo, Enrique
    Perez de Olaguer, Joaquim
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 177 - 177
12345